BioCentury | Mar 22, 2021
Product Development

Genomics plc puts polygenic risk scores to the test with NHS pilot

...approach.On March 1, Genomics plc raised $30 million in a venture round from Foresite Capital, F-Prime Capital Partners...
BioCentury | Jan 12, 2021
Emerging Company Profile

Atalanta’s next-gen RNAi branches deeper into brain, hooks Biogen and Genentech

...F-Prime CapitalCEO: Alicia SecorTARGETSHTT - Huntingtin Karen Tkach Tuzman F-Prime Capital Partners Genentech...
BioCentury | Jan 4, 2021
Deals

Angelini adds registrational epilepsy program via $610M Arvelle takeout

...in Arvelle include NovaQuest Capital Management, LSP, BRV Capital Management, Andera Partners, H.I.G. BioHealth Partners, F-Prime Capital Partners...
BioCentury | Jun 11, 2020
Finance

Checkmate raises $85M series C to support new indications for TLR9 agonist

...fund of the American Cancer Society, as well as existing investors Sofinnova Investments, venBio Partners, F-Prime Capital Partners...
...Opdivo (Other) Checkmate Pharmaceuticals Inc. Merck & Co. Inc. Longitude Capital Decheng Capital Medicxi Ventures Omega Funds Clough Capital Partners Sectoral Asset Management Inc. F-Prime Capital Partners Novo...
BioCentury | May 28, 2020
Finance

May 27 Quick Takes: Atara raises $176M on back of MS data; plus Exscientia’s $60M C round, Geron, Silence, Arvelle, ViaCyte, Poxel, Accure, Tollys

...A. Investors included NovaQuest Capital Management, BRV Capital Management, LSP, H.I.G. BioHealth Partners, Andera Partners, F-Prime Capital Partners...
BioCentury | Apr 28, 2020
Finance

April 27 Quick Takes: Avalyn raises $35M for fibrosis therapies, plus Actym, LifeSprout, HebeCell, Compass, Immunomic

...by Norwest Venture Partners with participation from new investor Pivotal bioVenture Partners and existing investors F-Prime Capital Partners...
BioCentury | Sep 27, 2019
Financial News

Sept. 27 Financial Quick Takes: Beam hops into IPO queue; plus Amryt, T3, Junshi, Newronika

...2021. Arch Venture Partners has a 23% stake in the company ahead of the offering; F-Prime Capital Partners...
BioCentury | Apr 25, 2019
Finance

The academic founders' conundrum

...Caufield & Byers Preclin Cancer 2015 Compass Therapeutics LLC Cambridge, Mass. $132.0 OrbiMed Advisors , F-Prime Capital Partners...
...2014 NodThera Ltd. Cambridge, U.K. $37.1 Sofinnova Partners , 5AM Ventures , Epidarex Capital , F-Prime Capital Partners...
BioCentury | Apr 17, 2019
Emerging Company Profile

Nocion: Targeting pain neurons and nothing else

With a $27 million series A co-led by Canaan and F-Prime Capital announced Wednesday, Nocion thinks it could replace opioids in a range of tissue-localized indications, starting with cough. The company is aiming to minimize...
BioCentury | Feb 16, 2019
Emerging Company Profile

NodThera: Inhibiting the inflammasome for NASH

...Undisclosed Funds raised: £28 million ($37 million) Investors: Sofinnova Partners, 5AM Ventures, Epidarex Capital and F-Prime Capital Partners...
Items per page:
1 - 10 of 55
BioCentury | Mar 22, 2021
Product Development

Genomics plc puts polygenic risk scores to the test with NHS pilot

...approach.On March 1, Genomics plc raised $30 million in a venture round from Foresite Capital, F-Prime Capital Partners...
BioCentury | Jan 12, 2021
Emerging Company Profile

Atalanta’s next-gen RNAi branches deeper into brain, hooks Biogen and Genentech

...F-Prime CapitalCEO: Alicia SecorTARGETSHTT - Huntingtin Karen Tkach Tuzman F-Prime Capital Partners Genentech...
BioCentury | Jan 4, 2021
Deals

Angelini adds registrational epilepsy program via $610M Arvelle takeout

...in Arvelle include NovaQuest Capital Management, LSP, BRV Capital Management, Andera Partners, H.I.G. BioHealth Partners, F-Prime Capital Partners...
BioCentury | Jun 11, 2020
Finance

Checkmate raises $85M series C to support new indications for TLR9 agonist

...fund of the American Cancer Society, as well as existing investors Sofinnova Investments, venBio Partners, F-Prime Capital Partners...
...Opdivo (Other) Checkmate Pharmaceuticals Inc. Merck & Co. Inc. Longitude Capital Decheng Capital Medicxi Ventures Omega Funds Clough Capital Partners Sectoral Asset Management Inc. F-Prime Capital Partners Novo...
BioCentury | May 28, 2020
Finance

May 27 Quick Takes: Atara raises $176M on back of MS data; plus Exscientia’s $60M C round, Geron, Silence, Arvelle, ViaCyte, Poxel, Accure, Tollys

...A. Investors included NovaQuest Capital Management, BRV Capital Management, LSP, H.I.G. BioHealth Partners, Andera Partners, F-Prime Capital Partners...
BioCentury | Apr 28, 2020
Finance

April 27 Quick Takes: Avalyn raises $35M for fibrosis therapies, plus Actym, LifeSprout, HebeCell, Compass, Immunomic

...by Norwest Venture Partners with participation from new investor Pivotal bioVenture Partners and existing investors F-Prime Capital Partners...
BioCentury | Sep 27, 2019
Financial News

Sept. 27 Financial Quick Takes: Beam hops into IPO queue; plus Amryt, T3, Junshi, Newronika

...2021. Arch Venture Partners has a 23% stake in the company ahead of the offering; F-Prime Capital Partners...
BioCentury | Apr 25, 2019
Finance

The academic founders' conundrum

...Caufield & Byers Preclin Cancer 2015 Compass Therapeutics LLC Cambridge, Mass. $132.0 OrbiMed Advisors , F-Prime Capital Partners...
...2014 NodThera Ltd. Cambridge, U.K. $37.1 Sofinnova Partners , 5AM Ventures , Epidarex Capital , F-Prime Capital Partners...
BioCentury | Apr 17, 2019
Emerging Company Profile

Nocion: Targeting pain neurons and nothing else

With a $27 million series A co-led by Canaan and F-Prime Capital announced Wednesday, Nocion thinks it could replace opioids in a range of tissue-localized indications, starting with cough. The company is aiming to minimize...
BioCentury | Feb 16, 2019
Emerging Company Profile

NodThera: Inhibiting the inflammasome for NASH

...Undisclosed Funds raised: £28 million ($37 million) Investors: Sofinnova Partners, 5AM Ventures, Epidarex Capital and F-Prime Capital Partners...
Items per page:
1 - 10 of 55